Overview
Maarten Larmuseau is co-founder and CEO of Nuclivision, a Ghent-based healthtech company developing AI-enhanced software for nuclear imaging.
Maarten Larmuseau is co-founder and chief executive of Nuclivision, and is based in Ghent. He has led the company as CEO since January 2023, having joined it as a senior data scientist in October 2022, a role he held until February 2023.
Before that, he was a doctoral researcher at Universiteit Gent from October 2017 to October 2022. He studied at Ghent University throughout, taking a bachelor's degree in engineering physics between 2011 and 2014, followed by master's degrees in engineering physics and in biomedical engineering, both completed in 2016, and a master's degree in business engineering with a specialisation in data science in 2017.
Career history
In the news
- What if we could get more information from the PET scans we’re already performing? Only four days until our first webinar where Prof. Silvia Morbelli, MD discusses how better image quality could open the door to extracting more clinically relevant information from a single scan. Join us for a clinical deep-dive into how AI is transforming PET imaging in Alzheimer's disease management and explore together with Maarten Larmuseau how AI is transforming PET scanning today and what's on the horizon. 📅 Monday, September 22nd | 4:30
- On the road! 🚗 The (in)famous “European summer” has clearly ended 😅 In the past 24 hours I had the opportunity to pitch nuclivision at three different events. Let’s go 🚀🚀
- Excited for my first ever appearance in a webinar next week! Amyloid PET imaging can significantly increase our understanding of Alzheimer’s disease (AD) and help in patient selection for the new AD treatments that are on the market. In Europe, the adoption of Amyloid PET is slower than in the US, mainly due to the high tracer cost and limited reimbursement. AI-based denoising allows to optimize amyloid scanning in two ways: - early phase: an enhanced amyloid scan can act as a surrogate for an FDG scan, reducing the need
- Some exciting news from Erlangen Germany, where yesterday an interesting study was published by the group of Florian Rosar from Universitätsklinikum Erlangen. They showed how PSMA labelled with Tb-161 leads to high and stable uptake in tumors, in patients with metastastic castration resistant prostate cancer (mRCPC). Although the sample size is still small, the results look really promising. Why is this important? The promise of radioligand therapy is that you can see what you treat and treat what you see. It is basically
- Below a picture of me and my co-founder Tomas Brants, almost 4 years ago, when we had just started the adventure that would be called nuclivision We definitely look older now and perhaps have gotten a little wiser too 😉 When we started, we were convinced that the biggest impact we would have, was to reduce the radioactive exposure to patients, especially in children and pregnant women. Four years later, I am no longer convinced about this. Our biggest impact is that we can accelerate the time it takes for a patient to get a
- We have some exciting news! Nuclivision is hosting its first-ever webinar. We're thrilled to welcome Prof Silvia Morbelli for a clinical deep-dive into how AI is transforming PET imaging in Alzheimer's disease management and she is joined by our CEO Maarten Larmuseau exploring further what impact AI can have on PET scanning today and what's on the horizon. If you work in nuclear medicine or neurology and want to understand where AI in PET imaging is headed, don't miss this one. Register here → https://lnkd.in/eNp355zK
- A bit late to the party, but a huge congrats to the team of ABSCINT and especially Karine Clauwaert! 🥳🥳 Over the last year, I very much enjoyed the occasional coffee with her, talking on topics ranging from how to run a company to fundamental biology. No spreadsheets, no ARRs, just a shared interest in finding out what is possible with nuclear medicine and some vivid discussions about the underlying biology. In my previous life, I worked a lot on genomics and transcriptomics, very interesting fields, but the biggest challenge
- Never a dull moment in nuclear medicine ☢️ but the last 5 days have been nothing short of amazing: July 31: FDA approves Pluvicto for PSMA-positive metastatic hormone sensitive prostate cancer. Radioligand therapy is no longer a last resort, it moves earlier in the disease, with roughly double the eligible patient population. Aug 3: Curium moves to acquire Lantheus for up to $8B. Although these two events are seemingly unrelated at first glance, they both show that things are moving fast, and the money is following. Remember
Related profiles
This page shows public professional information only, each fact cited. Is this you? send a correction, or ask for removal within 24 hours, no questions asked.